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Referat: Left ventricular diastolic dysfunction (LVDD) is common in the general population, but its 
prevalence in atrial fibrillation (AF), predictors for LVDD in AF and the association between LVDD 
and AF-related symptom severity has not been well-studied.
In 124 consecutive patients (mean age 61 ± 11years, 60 % male) with paroxysmal (n=70) or 
persistent AF (n=54) referred for AF catheter ablation, LVDD was evaluated according to current 
guidelines using  transthoracic echocardiography.  AF-related symptom severity was quantified 
using the EHRA score. 
LVDD was present in 46 patients (37 %). In uni- and multivariable regression analysis, age (OR 
1.068 per year, 95 % CI 1.023 – 1.115, p=.003) and persistent AF (OR 2.427 vs paroxysmal AF, 
95 % CI 1.112 – 5.3, p=.026) were associated with LVDD. LVDD was found in 11 % with mild 
AF symptoms (n=27) as opposed to 44 % in patients with moderate- severe AF symptoms (n=97, 
p=.002). Thus, the OR for moderate-severe AF symptoms was 6.368 (1.797 – 22.568, p=.004) in 
the presence of LVDD. 
LVDD (1) occurs frequently in AF, (2) is associated with advancing age and AF progression and (3) 
is correlated with symptom severity in AF.
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1 Introduction 
1.1 Left ventricular diastolic dysfunction
1.1.1 Definition and pathophysiology
The optimal performance of the left ventricle (LV) is dependent of ability to smoothly cycle 
between two states: a stiff, contracting chamber in which the pressure is rising rapidly leading to 
ejection of the  stroke volume at arterial pressures (systole) and a compliant reservoir that allows 
the passive filling from low left atrial (LA) pressure (diastole). 
The impairment of one of those components leads to deterioration of the whole system causing 
symptoms of heart failure. 
In case of left ventricular diastolic dysfunction (LVDD) the distortion of the ventricle capacity to 
relax, stretch and passively fill at low pressure state during diastole results in development of 
chronic heart failure with normal left ventricular ejection fraction (HFNEF) (1).
Elevated filling pressures are the main physiologic consequence of diastolic dysfunction. There 
are considered elevated when the mean pulmonary capillary wedge pressure (PCWP) is >12 mm 
Hg or  when the  left  ventricular  end-diastolic  pressure  (LVEDP)  is  >16 mm Hg (1).  Those 
pathological changes result in fatigue and breathlessness which are the first and most frequent 
symptoms of HFNEF. Through further aggravating of the underling LVDD the development of 
typical signs of heart failure such as lung crepitations, pulmonary edema, ankle swelling and 
hepatomegaly can be observed  in advanced stages (1).
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The hemodynamic characteristics of LVDD can be caused by different factors and mechanisms. 
Besides external parameters such as the influence of the pericardium and the elevated pulmonary 
airway pressure, two processes can mainly affect pressure development in diastole. 
At the beginning of the diastole the active relaxation of the myocardium and the recoil effect of 
elastic energy cumulated in the elastic fibers of extracellular matrix, which was stored in the 
myocardium during previous systole plays a key role. This ability of myocardium determines 
atrioventricular pressure gradient and ventricular filling rate. This relaxation of myocytes is an 
active adenosine triphosphate consuming process concerning the calcium homeostasis of cardiac 
myocytes. In patients with LVDD, the process of relaxation is slowed, resulting in a delay of 
mitral valve opening and a decrease in early diastolic atrioventricular pressure gradient. These 
effects lead to an impairment of early ventricular filling.  This pathological hemodynamic may 
not  be suffice to increase diastolic  filling pressures at  low heart  rates,  as there is  still  some 
reserve resulting from prolonged diastole,  but at higher heart rates (e.g. in case of AF) it might 
elevated filling pressures to the level where symptoms of HFNEF can occur. 
Apart  from  relaxation,  the  ventricular  filling  process  is  mainly  influenced  by  the  chamber 
stiffness,  which represents the passive elastic  capacity of the ventricle.  This is  dependent on 
cellular  and histological  structure  of  myocardium (cardiomyocytes  and extracellular  matrix), 
myocardial tone, chamber geometry, and wall thickness. 
Those  fundamental  mechanisms  of  LVDD  can  be  influenced  by  different  comorbidities  or 
conditions involving structural or histological remodeling (2) or even subcellular alterations (3). 
Therefore, certain systemic and cardiac diseases predispose to the development of LVDD with 
subsequent evolution of heart failure. 
-5-
- Introduction -
Although diastolic  dysfunction is  not uncommon in patients with normal wall  thickness,  LV 
hypertrophy is among the most important reasons for development of LVDD (4). In patients with 
HFNEF,  concentric  hypertrophy (increased  mass  and relative  wall  thickness),  or  remodeling 
(normal mass but increased relative wall thickness), can be frequently observed. Because of the 
high prevalence of hypertension, especially in the older population, LV hypertrophy is common, 
and hypertensive heart disease is the most common abnormality leading to diastolic heart failure 
(4). 
Diabetic  cardiomyopathy is  characterized by altered myocardial  and vascular function in the 
absence of macroscopic coronary artery disease, hypertension, and valvular or congenital heart 
disease (5). These patients exhibit changes in cardiac structure such as ventricular and myocyte 
hypertrophy, perivascular fibrosis, increased deposition of matrix collagen which were observed 
in different studies (6,7). Furthermore, in diabetic patients a different composition of myocardial 
cell membrane lipids, cellular triglycerides my be observed (8). The microvascular changes e.g. 
endothelial dysfunction and the mediated fibrosis increases arterial stiffness (7). In those patients 
the diastolic abnormalities are usually the first cardiac pump dysfunctions that can be detected 
(9).
Since a ventricular diastolic relaxation  is an energy-dependent process, it may be impaired by 
conditions decreasing energy availability such as ischemia (10). Therefore, in a series of studies 
a high prevalence of LVDD was associated with coronary artery disease (11,12).
1.1.2 Echocardiographic diagnostic methods 
 
The identification of the elevated filling pressure had been initially based on an interventional 
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measurements  during  catherisation.  However,  with  the  development  of  modern 
echocardiographic  techniques  enabling  non-invasisve  assessment  of  diastolic  function, 
echocardiography has gained a central role in the evaluation of LVDD over the past two decades.
Today two echocardiographic measurements are widely acknowledge and recommended by the 
guidelines (13) for the diagnosis of LVDD: 1) mitral inflow pattern obtained by the use of pulse  
wave Doppler and 2) the mitral annular velocities.
Primary measurements of mitral inflow include the peak early filling (E-wave) and late diastolic 
filling (A-wave) velocities, the E/A ratio, deceleration time (DT) of early filling velocity (Figure 
1).  The values of mitral E/A ratio and DT identify different mitral inflow patterns which are 
specific for three stages of LVDD. They include impaired LV relaxation pattern, pseudonormal 
LV filling (PNF) and restrictive LV filling. 
Figure 1.  A) mitral inflow pattern obtained by the use of pulse wave Doppler and B) the mitral 
annular velocities depicted by tissue Doppler.
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However,  this  method  has  serious  limitation  reducing its  diagnostic  value  as  the  LV filling 
patterns have a U-shaped relation with LV diastolic function, meaning that similar values can be 
seen in healthy normal subjects and patients with LVDD. Therefore, the diagnosis should not be 
based on mitral inflow pattern alone but be combined with the tissue Doppler measurements.
The  mitral  annular  velocities  measured  by  tissue  Doppler,  so  called  e',  is  a  more  sensitive 
parameter for abnormal myocardial early diastolic function than mitral variables and can be used 
to  draw  inferences  about  LV  relaxation  process.  Once  mitral  flow,  annular  velocities  are 
acquired, it is possible to compute additional ratio. The ratio include inflow E velocity to tissue 
Doppler  e'  (E/e  '  ratio)(14),  which  plays  an  important  role  in  the  estimation  of  LV filling 
pressures. This so-called filling index, correlates well with LV filling pressure and allows for 
diagnosis of diastolic dysfunction if it reaches high values. 
Based  on  this  comprehensive  echocardiographic  measurements,  the  current  guidelines  (13) 
recommend grading of LVDD in mild or grade I (impaired relaxation pattern),  moderate  or 
grade II  (PNF),  and severe (restrictive  filling)  or  grade III  (Figure 2).  In patients with mild 
diastolic dysfunction, the mitral E/A ratio is < 0.8, DT is >200 ms,  and the E/e´ ratio is <8. In 
patients  with  moderate  diastolic  dysfunction  (grade  II),  the  mitral  E/A ratio  is  0.8  to  1.5 
(pseudonormal) and decreases by50% during the Valsalva maneuver, the E/e´ (average) ratio is 9 
to  12,  and  e´  is  <8  cm/s.   Grade  II  diastolic  dysfunction  represents  impaired  myocardial 
relaxation  with  mild  to  moderate  elevation  of  LV  filling  pressures.  With  severe  diastolic 
dysfunction (grade III),  restrictive LV filling occurs with an E/A ratio  >  2, DT<160 ms and 
average E/e´ ratio >13.
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Figure 2. Grading of LVDD 
1.1.3 Increasing prevalence and importance of left ventricular diastolic
dysfunction
About half of patients with new diagnoses of heart failure have normal or near normal global 
ejection fractions (15-21). Although the term diastolic heart failure has been abandoned,  LVDD 
is considered to be the main pathophysiologic mechanisms in those patients. 
The average age of those patients tends to be older than those with reduce EF and in most studies 
the majority have been women and have a history of hypertension (15-16). Therefore, the aging 
of the populations combined with increasing prevalence of hypertension, which is often poorly 
treated,  indicate a substantial  increase in the number of patients with HFNEF in foreseeable 
future (22).
Although, in comparison to heart  failure secondary to reduce of EF the HFNEF rarely have 
fulminate course and the signs and symptoms remain subclinical for long time,  the outcome 
might be similar. 
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Epidemiological studies have shown that the annual mortality rate approaches 15% for patients 
with HFNEF, which is a similar rate as in patients with reduce EF (15,20,23). Importantly, even 
in asymptomatic patients with grade I LVDD,  diastolic dysfunction was associated with a 5-fold 
higher 3-year to 5-year mortality in comparison with subjects with normal diastolic function 
(24).
This issue is of great importance as till today no evidence based therapy have been established 
Since previously patients with HFNEF have been excluded from clinical trials on the basis of a 
normal LV ejection fraction there is little evidence to guide treatment. Nevertheless, multiple 
drugs  which  are  used  for  therapy  of  systolic  heart  failure,  including  beta-blockers,  sartans, 
diuretics and cardiac glycosides, were tested in large trials (24-30). Most of the agents had a 
modest impact in preventing hospital admissions and improving symptoms and signs of HFNEF 
but non had an significant effect on cardiovascular death.
1.2 Link between left ventricular diastolic dysfunction and atrial 
fibrillation
The  interactions  between  AF  and  LVDD  are  frequently  of  bidirectional  nature  and  can  be 
explained on haemodynamical, structural or even cellular level.  
For instance, patients with abnormal diastolic function are frequently hospitalised due to signs of 
heart failure (23) and the odd ratio increases in presence of AF (31). An possible explanation of 
that observation would be a strong dependence of the hemodynamic performance of the whole 
system on  intact  atrial  function  since  the  functional  reserve  of  impaired  ventricle  is  highly 
reduced. Consequently, the rapid deterioration associated with onset of AF might be leading to 
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increased hospitalisation or even influence outcome (32,33).
The presence of LVDD has been also proven to be correlated with higher thromboembolic risk   in 
AF patients (34). Increased ventricular ‘stiffness’ and poor myocardial compliance, which are 
associated with LVDD, may cause abnormal blood flow characteristics,  which may promote 
thrombogenesis. In addition, worse atrial function and stasis, which can be secondary to elevated 
LV filling pressures, may boost prothrombotic processes. LVDD may also influence the cellular 
balance of the whole cardiovascular system. Preliminary study showed a significant correlation 
between  diastolic  dysfunction  and  functional  impairment  of  endothelial  cells,  suggesting 
increased thrombogenic potential (35). Furthermore, LVDD may be associated with increased 
prothrombotic tendency at the molecular level. It has been described that higher intravascular 
fibrin turnover,  reflected by plasma D-dimer concentration,  can be observed in patients with 
LVDD, when compared to a normal population (36).
The  increasing  availability  and  improved  techniques  of  invasive  electrophysiology  revealed 
further interactions between LVDD and AF as it has been shown that patients with LVDD have 
more  severe  LA low-voltage  substrate,  when  compared  to  the  patients  with  normal  cardiac 
function (37). Since LA diameter and volume increase with an increasing severity of the diastolic 
dysfunction it can also result in a chronic diastolic atrial pressure overload, and subsequent LA 
remodeling.
Consequently, recent reports suggested that hemodynamical alterations associated with impaired 
diastolic function can influence the results of catheter ablation (38-40). One possible mechanism 
of  AF  induction  and  therapy  failure  in  LVDD  patients  is  a  progressive  atrial  remodeling 
associated with an enlarged left atrium (41,42) and higher wall stress resulting from increased 
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LA  pressure  (43).  Those  processes  may  create  a  low-voltage  substrate  and  induce  focal 
automaticity, subsequently promote AF and worsen interventional outcomes.
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2 Aim of the study 
The aim of the study was to define prevalence and predictors for LVDD in AF and to examine 
the potential association between LVDD and AF-related symptom severity
3 Publication 
Kosiuk J, Van Belle Y, Bode K, Kornej J, Arya A, Rolf S, Husser D, Hindricks G, Bollmann A. 
Left ventricular diastolic dysfunction in atrial fibrillation: predictors and relation with symptom 
severity. J Cardiovasc Electrophysiol. 2012 Oct;23(10):1073-1082
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4 Discussion 
The  prevalence  of  LVDD was  relatively  high  (37%)  in  our  population  of  symptomatic  AF 
patients with mostly subclinical heart failure symptoms (71% in NYHA I, 24% in NYHA II, 5% 
NYHA III,  no patients with NYHA IV). In previous trials describing the population of patients 
admitted due to heart failure, the LVDD was observed in up to 30% of cases (4). 
Since a ventricular diastolic relaxation  is an energy-dependent process, it may be impaired by 
conditions decreasing energy availability such as ischemia (10). In fact, as shown in univariate 
analysis,  CAD was more common in patients with impaired diastolic  function (7% vs 22%, 
p=0.024). In our cohort, LVDD was also significantly correlated with advanced age (OR 1.068 
per year, 95 % CI 1.023 – 1.115, p=.003) as the reduced ventricular compliance is secondary to 
ageing process, since the ventricular stiffness increases with age and impairs diastolic function 
altering LV filling pressures (43). 
The interaction between this type of heart failure and AF is further confounded by evidence that 
diastolic dysfunction is itself a predictor of future AF (44). 
AF  impairs  cardiac  function  by  several  mechanisms,  such  as  the  loss  of  atrio-ventricular 
synchrony  and  atrial  contraction,  the  reduction  of  the  diastolic  filling,  the  induction  of  a 
tachycardia-induced cardiomyopathy. It can be therefore expected that the restoration of sinus 
rhythm will positively influence the ventricular function. Recent publications (39, 45)  support 
that  hypothesis  demonstrating  effectiveness  of  catheter  ablation  and  proving  existence  of 
additional benefits of this interventional approach.
Cha et  al.  (39) described an  improvement  of  LVDD of  at  least  1  grade  in  30% of  patients 
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undergoing  AF  catheter  ablation.  Similar  results  were  published  by  Reant  et  al.  (45)  who 
performed an echocardiographic study of LV diastolic and systolic function in a group of patients 
with paroxysmal and chronic AF who underwent catheter ablation, demonstrating that systolic 
and  diastolic  function  of  the  left  chamber  improved  after  AF  ablation.   Studies  on  patient 
ongoing  the  surgical  radiofrequency  ablation  also  demonstrated  reverse  remodelling  of  left 
ventricular diastolic and systolic function (46).  
The authors hypothesized that LV diastolic dysfunction can be attributed at least in part to AF. 
The suspected pathophysiological mechanisms were accounted to AF-induced stretch of the LA 
and  the  pulmonary  veins.  However,  another  potentially  important  reason  for  diastolic 
dysfunction is AF-induced alterations in the Ca2+ regulatory proteins that are responsible for 
both electrical and mechanical myocyte function. 
Our results mirrored the preliminary findings of other groups which showed an improvement of 
LVDD by cessation of AF or reducing the AF burden. Accordingly we observed an increased 
frequency and more  severe  LVDD in patients  with  a  persistent  form of  AF.  This  raises  the 
question  of  whether  AF contributes  to  development  of  diastolic  failure,  rather  than  to  be  a 
secondary problem.
Patients with abnormal diastolic function are frequently hospitalised due to signs of heart failure 
(23)  and the odd ratio increases in presence of AF (31) but little is known about AF symptoms in 
those group of patients. Moreover, little is known about determinants of symptoms or symptom 
severity in AF. The valvular heart disease as well as diuretics treatment are more likely to occur 
amongst  symptomatic  patients (47) but  no relationships between  presence of  LVDD and the 
severity of the AF symptoms were reported. Since valvular heart disease can cause alterations in 
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LV filling pattern and diuretics are generally used to treat symptoms of heart failure with normal 
ejection fraction both  conditions can by linked to LVDD. Consequently, LVDD may be seen as 
pathway explaining our results  showing that patients with LVDD have more severe symptoms 
related to AF. An possible explanation of that observation would be a strong dependence of the 
hemodynamic performance of the whole system on intact atrial  function since the functional 
reserve of impaired ventricle is highly reduced. 
5 Limitations 
This  study  included  a  highly-selected  patient  population,  i.e.  patients  referred  for  catheter 
ablation  had  drug-refractory  AF  in  most  cases.  None  of  the  patients  was  asymptomatic. 
Consequently, it is not known whether the described predictors can be found in the general AF 
population.  Due to  echocardiographic  limitations  only  patients  presenting with  sinus  rhythm 
were enrolled in this study.
6 Conclusion 
The left ventricular diastolic dysfunction occurs frequently in patients with atrial fibrillation  and 
is  associated  with  advancing age  and persistent  type  of  atrial  fibrillation.  Furthermore,   left 
ventricular  diastolic  dysfunction  is   associated  with  a  higher  symptom  severity  in  atrial 
fibrillation.
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7 Synopsis 
Dissertation zur Erlangung des akademischen Grades Dr. med. 
Left ventricular diastolic dysfunction in atrial fibrillation
Predictors and relation with symptom severity
Eingereicht von: Dr.med.univ. Jedrzej Kosiuk
Angefertigt am: Herzzentrum der Universität Leipzig 
Betreut von: Prof. Dr. med. A. Bollmann
August 2013 
Left ventricular diastolic dysfunction (LVDD) is common in the general population, but its prevalence in 
atrial fibrillation (AF), predictors for LVDD in AF and the association between LVDD and AF-related  
symptom severity has not been well-studied.
In 124 consecutive patients (mean age 61 ± 11years, 60 % male) with paroxysmal (n=70) or persistent AF 
(n=54) referred for AF catheter  ablation,  LVDD was evaluated  according to current  guidelines using 
transthoracic echocardiography. AF-related symptom severity was quantified using the EHRA score. 
LVDD was present in 46 patients (37 %). In uni- and multivariable regression analysis, age (OR 1.068 per 
year, 95 % CI 1.023 – 1.115, p=.003) and persistent AF (OR 2.427 vs paroxysmal AF, 95 % CI 1.112 – 
5.3, p=.026) were associated with LVDD. LVDD was found in 11 % with mild AF symptoms (n=27) as  
opposed to 44 % in patients with moderate-  severe AF symptoms (n=97,  p=.002).  Thus,  the OR for  
moderate-severe AF symptoms was 6.368 (1.797 – 22.568, p=.004) in the presence of LVDD.  
LVDD (1) occurs frequently in AF, (2) is associated with advancing age and AF progression and (3) is 
correlated with symptom severity in AF.
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